Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 48

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 48
---
2024.

• Completed the reorganization of our international operations, which included a sale of our EndoPredict business to Eurobio Scientific, enabling us to better align our resources to our domestic opportunities while continuing to serve key biopharma partners and patients globally.

• Established a number of research collaborations regarding the use of our Precise MRD test for breast cancer patients with leading cancer research institutions, including The University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, and the National Cancer Center Hospital East in Japan and a study partnership with Aptitude Health.

• The United States Patent and Trademark Office issued three new patents that further advance our ability to bring our tumor-informed, high-definition, MRD assay, Precise MRD, to market.

31

• Launched the Universal Plus Panel for Foresight Carrier Screen, which screens up to 272 genes associated with serious inherited conditions. • Launched early gestational age Prequel Prenatal Screen, which can be performed as early as eight weeks into pregnancy, which is the first and only prenatal cell-free DNA (cfDNA) screen that can be performed at this early gestational age. • Announced a collaboration with Flatiron Health, a leading health technology company dedicated to point of care solutions in oncology. This collaboration allows physicians to order our MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based EMR platform, OncoEMR. • We entered into a strategic partnership with jscreen™, a national organization that delivers education and access to genetic testing with a focus on high-risk populations. The collaboration combines our high-quality hereditary cancer and reproductive genetics products, MyRisk with RiskScore and Foresight Carrier Screen, with jscreen’s trusted education and genetic care navigation program. During the fourth quarter of 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test, under its commercial, individual exchange, and certain managed Medicaid plans. The change took effect for commercial and individual exchange benefit plans on January 1, 2025, and is expected to take effect for impacted managed Medicaid plans during the first half of 2025. The change in UnitedHealthcare coverage has negatively impacted our stock price and we anticipate that it will negatively impact our revenue, profitability, and cash flow in 2025 and thereafter. While we intend to continue our engagement with UnitedHealthcare regarding its decision